{"id":"bevacizumab-pemetrexed","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors require for growth. Pemetrexed is an antifolate antimetabolite that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, disrupting nucleotide synthesis and inducing apoptosis. Together, they provide complementary mechanisms targeting tumor vasculature and cancer cell proliferation.","oneSentence":"Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis and cell division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:10.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-squamous non-small cell lung cancer (NSCLC)"},{"name":"Mesothelioma"}]},"trialDetails":[{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT07472647","phase":"PHASE1, PHASE2","title":"SYS6090 Combination Therapy in Advanced Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-02-28","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06663306","phase":"PHASE1","title":"Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-12-09","conditions":"Lung Cancer (NSCLC), Leptomeningeal Metastasis","enrollment":19},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07420439","phase":"PHASE2","title":"Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-05-15","conditions":"Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)","enrollment":108},{"nctId":"NCT04837716","phase":"PHASE1","title":"Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-18","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT06783647","phase":"PHASE2","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-06-11","conditions":"Advanced Solid Tumour","enrollment":230},{"nctId":"NCT07398599","phase":"NA","title":"Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-02-15","conditions":"Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03768063","phase":"PHASE3","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-28","conditions":"Cancer","enrollment":1000},{"nctId":"NCT07103395","phase":"PHASE2","title":"A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Lung Cancer (NSCLC)","enrollment":56},{"nctId":"NCT05112965","phase":"PHASE3","title":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-12-01","conditions":"Neoplasms","enrollment":49},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT07134413","phase":"PHASE2","title":"QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-08","conditions":"NSCLC","enrollment":77},{"nctId":"NCT01951482","phase":"PHASE3","title":"Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non Squamous Non-small Cell Lung Cancer, Brain Metastases, Bevacizumab","enrollment":160},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT03762018","phase":"PHASE3","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-04-30","conditions":"Pleural Mesothelioma Malignant Advanced","enrollment":401},{"nctId":"NCT06839105","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-02-21","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor","enrollment":214},{"nctId":"NCT04042558","phase":"PHASE2","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","status":"COMPLETED","sponsor":"Centre Francois Baclesse","startDate":"2019-09-26","conditions":"NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation","enrollment":150},{"nctId":"NCT06971406","phase":"PHASE2","title":"High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Qiming Wang","startDate":"2025-05-15","conditions":"Non Small Cell Lung Cancer, EGFR Mutation, Leptomeningeal Metastases","enrollment":100},{"nctId":"NCT03786692","phase":"PHASE2","title":"Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2019-09-04","conditions":"Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":117},{"nctId":"NCT04512430","phase":"PHASE2","title":"Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients","status":"TERMINATED","sponsor":"Fundación GECP","startDate":"2020-12-02","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":4},{"nctId":"NCT06643000","phase":"NA","title":"Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-12-20","conditions":"Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation","enrollment":60},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT06812871","phase":"PHASE2","title":"High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":30},{"nctId":"NCT06775275","phase":"PHASE2","title":"A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2024-09-24","conditions":"Resectable Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT04245085","phase":"PHASE2","title":"ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2020-09-29","conditions":"EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC","enrollment":95},{"nctId":"NCT03872661","phase":"PHASE2","title":"Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-01","conditions":"Lung Cancer Stage III","enrollment":36},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT04973293","phase":"NA","title":"Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-10-01","conditions":"Lung Neoplasm Malignant","enrollment":20},{"nctId":"NCT06537297","phase":"PHASE2","title":"Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases","status":"NOT_YET_RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2024-09-30","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06543069","phase":"PHASE2","title":"Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-31","conditions":"Malignant Peritoneal Mesothelioma, Advanced","enrollment":28},{"nctId":"NCT05055908","phase":"PHASE3","title":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-10-01","conditions":"Lung Cancer","enrollment":12000},{"nctId":"NCT00998166","phase":"PHASE2","title":"A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-06","conditions":"Non-Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT05284539","phase":"PHASE2","title":"Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2022-04-01","conditions":"Non Small Cell Lung Cancer","enrollment":760},{"nctId":"NCT04322578","phase":"PHASE2","title":"Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-03-24","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT05266846","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2024-05-29","conditions":"ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy","enrollment":78},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT06334757","phase":"PHASE2","title":"Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-05-08","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT05930665","phase":"PHASE2","title":"Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-01","conditions":"Pleural Mesothelioma","enrollment":38},{"nctId":"NCT05329025","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-06-01","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT05812534","phase":"PHASE2","title":"Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2023-12","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":36},{"nctId":"NCT03952403","phase":"PHASE3","title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-12-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":643},{"nctId":"NCT01107626","phase":"PHASE3","title":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2010-10-25","conditions":"Lung Cancer","enrollment":1516},{"nctId":"NCT02045446","phase":"PHASE2","title":"Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-02","conditions":"Stage IV Non-Small Cell Lung Cancer","enrollment":29},{"nctId":"NCT03991403","phase":"PHASE3","title":"Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2019-08-27","conditions":"Non-small Cell Lung Cancer","enrollment":228},{"nctId":"NCT05267366","phase":"PHASE2","title":"Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2022-02-01","conditions":"PFS, OS","enrollment":117},{"nctId":"NCT00651456","phase":"PHASE2, PHASE3","title":"Mesothelioma Avastin Plus Pemetrexed-cisplatin Study","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2008-02","conditions":"Mesothelioma","enrollment":448},{"nctId":"NCT01705184","phase":"PHASE2","title":"Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung","enrollment":120},{"nctId":"NCT03713944","phase":"PHASE2","title":"Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Nasser Hanna","startDate":"2018-11-15","conditions":"NSCLC Stage IV, NSCLC, Recurrent","enrollment":30},{"nctId":"NCT02120807","phase":"PHASE1","title":"Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-04-15","conditions":"Stage IV Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT05675033","phase":"PHASE2","title":"Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-01-10","conditions":"Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor","enrollment":50},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT05648071","phase":"PHASE3","title":"First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-12-01","conditions":"Advanced Non-squamous Non-Small-Cell Lung Cancer","enrollment":60},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT04861948","phase":"PHASE1","title":"IBI188 Combination Therapy in Solid Tumors","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-05-25","conditions":"Solid Tumors, Lung Adenocarcinoma, Osteosarcoma","enrollment":9},{"nctId":"NCT05334277","phase":"PHASE2","title":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-05-06","conditions":"Non-small Cell Lung Cancer","enrollment":280},{"nctId":"NCT05507606","phase":"PHASE2","title":"Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT04683965","phase":"PHASE2","title":"Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-01-01","conditions":"Colorectal Neoplasms","enrollment":27},{"nctId":"NCT03843853","phase":"PHASE2","title":"Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer","status":"WITHDRAWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-05-01","conditions":"Colorectal Neoplasms","enrollment":""},{"nctId":"NCT05273814","phase":"PHASE1","title":"Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-08-01","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05394233","phase":"PHASE2","title":"Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-06-01","conditions":"Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation","enrollment":20},{"nctId":"NCT00456261","phase":"PHASE2","title":"First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2007-03","conditions":"Lung Cancer","enrollment":110},{"nctId":"NCT02743923","phase":"PHASE3","title":"Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-04","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":203},{"nctId":"NCT05132413","phase":"PHASE3","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":"Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer","enrollment":561},{"nctId":"NCT04405674","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT00402883","phase":"PHASE2","title":"Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-11","conditions":"Lung Cancer","enrollment":5},{"nctId":"NCT00948675","phase":"PHASE3","title":"Study of Participants With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09-01","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":361},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT00533429","phase":"PHASE2","title":"Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT00438204","phase":"PHASE2","title":"Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2006-05","conditions":"Lung Cancer","enrollment":39},{"nctId":"NCT00295503","phase":"PHASE2","title":"Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2006-02","conditions":"Mesothelioma","enrollment":53},{"nctId":"NCT01633970","phase":"PHASE1","title":"A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-07-11","conditions":"Cancer","enrollment":240},{"nctId":"NCT04517526","phase":"PHASE2","title":"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-11-01","conditions":"Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT","enrollment":60},{"nctId":"NCT01803282","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-29","conditions":"Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer","enrollment":236},{"nctId":"NCT01063283","phase":"NA","title":"Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2010-03","conditions":"Advanced Non-squamous Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT02200354","phase":"PHASE2","title":"The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab","status":"TERMINATED","sponsor":"Kobe City General Hospital","startDate":"2014-07","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":20},{"nctId":"NCT00234052","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-07-28","conditions":"Lung Cancer","enrollment":51},{"nctId":"NCT01116219","phase":"PHASE2","title":"Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-06","conditions":"Lung Cancer","enrollment":149},{"nctId":"NCT01263782","phase":"PHASE2","title":"BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-05-17","conditions":"Lung Cancer","enrollment":64},{"nctId":"NCT03647956","phase":"PHASE2","title":"Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2018-10-01","conditions":"NSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation","enrollment":40},{"nctId":"NCT00614822","phase":"PHASE2","title":"Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Christiana Care Health Services","startDate":"2007-11","conditions":"Non Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT02162537","phase":"PHASE3","title":"Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2013-12","conditions":"Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer, Adenocarcinoma of Lung Metastatic to Brain","enrollment":95},{"nctId":"NCT02507518","phase":"PHASE2","title":"Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"Centre Henri Becquerel","startDate":"2013-12","conditions":"Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT00619424","phase":"PHASE1","title":"A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-15","conditions":"Lung Cancer, Non-Small Cell","enrollment":58},{"nctId":"NCT01344824","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2010-03","conditions":"Lung Cancer","enrollment":38},{"nctId":"NCT01351415","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-06-25","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":485}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin®","ALIMTA®"],"phase":"phase_3","status":"active","brandName":"Bevacizumab + Pemetrexed","genericName":"Bevacizumab + Pemetrexed","companyName":"PD Dr. med. Wolfgang Schuette","companyId":"pd-dr-med-wolfgang-schuette","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis and cell division. Used for Non-squamous non-small cell lung cancer (NSCLC), Mesothelioma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}